CERTAINTY holds first EC monitoring meeting

In September, the CERTAINTY consortium successfully held its first official monitoring meeting with the European Commission, marking a key checkpoint in our Horizon Europe journey under Grant Agreement No. 101136379.

The meeting brought together the Project Officer team, three external scientific experts, and Work Package leaders from across the consortium. Coordinated by the Project Management Office, the session aimed to evaluate the project's progress, ensure alignment with expected outcomes, and gather feedback to further strengthen our path forward.

Each Work Package lead presented technical achievements, results to date, and planned next steps. The discussions reflected the project’s multidisciplinary scope, covering single-cell data integration, digital infrastructure, patient engagement, clinical protocols, and regulatory considerations.

Initial feedback from the reviewers was highly positive, confirming that CERTAINTY is on a strong path toward its ambition of developing a virtual twin to personalise CAR T cell therapy for patients with multiple myeloma.

CERTAINTY brings together 17 partners from academia, research institutions, industry, and a patient organisation, forming a diverse and expert-driven network. This monitoring meeting showcased the strength of this collaboration and our shared commitment to advancing precision medicine and digital innovation in cancer care.